The significant clinical outcomes of anti-CD19 CAR-T cells in MM justified the creation of CAR-T cells targeting other antigens expressed on myeloma cells, including CD38 (83), CD138 (84), SLAMF7 (85), SLAMF3 (86), CD56 (87), NKG2D (88), and most successfully BCMA (89). Here, TNFRSF17 is linked to Miyoshi myopathy.